Corporate Reputation of Pharma in 2018 - Views of 100 Mental Health Patient Groups - ResearchAndMarkets.com

DUBLIN--()--The "The Corporate Reputation of Pharma in 2018 - The Patient Perspective - Mental Health Edition The Views of 100 Mental Health Patient Groups" report has been added to ResearchAndMarkets.com's offering.

This the 4th edition of 'The Corporate Reputation of Pharma - from the Perspective of Mental-Health Patient Groups'. The 2018 results are drawn from a survey of patient groups worldwide, conducted November 2018 - February 2019.

Profile of 2018's respondent mental-health patient groups: 100 respondent mental-health patient groups. 48 specialise in all types of mental health; 15 specialise in schizophrenia; 11 in ADHD; 6 in bipolar disorder; 4 in addiction; 2 in anxiety; 1 in eating disorders; and the others focus on other mental-health issues. Respondent groups are based in 34 countries, including the United States [13], Spain [11], and Italy [9]. 54% are national patient groups; 8% have an international geographic remit; the rest are regional (within one country), or local.

Mental-health patient-group partnerships with industry: 46% of the mental-health patient groups have worked with one or more pharma companies.

Company analyses: The following 15 pharma companies were analysed by the 100 mental-health patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation:

  • Allergan
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • GSK
  • Janssen
  • Lundbeck
  • Otsuka
  • Pfizer
  • Roche/Genentech
  • Sanofi
  • Takeda/Shire
  • Teva

Key Findings Across the Pharma Industry

The attitudes of mental-health patient groups towards the pharmaceutical industry have fluctuated over the four years that the analyst has been analysing their viewpoints; but, overall, mental-health patient groups are becoming less positive about the industry's corporate reputation. In 2015, 38% of respondent mental-health patient groups stated that the industry had an Excellent or Good corporate reputation; in 2018, the equivalent figure was down to just 24%.

Much appears to hinge on the pharma industry's R&D output in the therapy area. 2015's respondent mental-health patient groups were far more confident than those of 2018 that pharma had the ability to innovate, and to produce high-quality products of value to people with a mental-health condition.

As many as 67% of the 2015 respondents thought pharma Excellent or Good at innovation, and 73% said the same for pharma's ability to provide high-quality products. In 2018, those figures had fallen to 27% and 39% respectively. These negative views on pharma R&D dominate mental-health patient groups' thinking about the pharmaceutical industry today.

Yet, despite the generally gloomy opinions, a small number of 2018's respondent mental-health patient groups did comment very favourably on recent initiatives taken by some pharmaceutical companies to deliver both new products, and new approaches, in the therapy area.

Key Topics Covered

  • Executive Summary
  • Mental-Health Patient-Group Relationships With Pharma, 2018
  • Rankings Of 15 Pharma Companies, 2018 v. 2017
  • Among Mental-Health Patient Groups Familiar With The Companies Rankings Of 4 Pharma Companies, 2018 v. 2017
  • Among Mental-Health Patient Groups That Work Or Partner With The Companies
  • Profiles Of The 15 Pharma Companies, 2018 v. 2017

Appendices

  • Appendix: What The 100 Mental-Health Patient Groups Say On Pharma, And How The Industry Can Improve

Tables & Charts

  • Percentage Of Respondent Patient Groups Each Stating That The Pharmaceutical Industry Was Excellent Or Good At Innovation And The Provision Of Highquality Products - Mental-Health Patient Groups V. Patient Groups Across All Therapy Areas
  • The Rankings Of Big Pharma' At Corporate Reputation (Among Mental-Health Patient Groups Familiar With The Companies), 2018
  • Mental-Health Patient Groups: Familiarity, And Partnerships, With Pharma Companies, 2018
  • The Types Of Relationships That Mental-Health Patient Groups Have With Pharma Companies, 2018
  • The Corporate Reputation Of The Pharmaceutical Industry, 2018 V. 2017 - Compared With Eight Other Healthcare Sectors, According To Mental-Health Patient Groups
  • The Corporate Reputation Of The Pharmaceutical Industry, 2015-2018 - According To Mental-Health Patient Groups
  • How Good Or Bad The Pharmaceutical Industry Was In 2018 At Carrying Out Specific Activities, According To Mental-Health Patient Groups [Chart And Table]
  • How Good Or Bad The Pharmaceutical Industry Was In 2018 At Carrying Out Specific Activities, According To Mental-Health Patient Groups - Compared With Previous Years
  • Rankings Of Individual Pharma Companies, 2018 V. 2017 - According To Mentalhealth Patient Groups Familiar With The Company
  • Rankings Of Individual Pharma Companies, 2018 V. 2017 - According To Mentalhealth Patient Groups That Work Or Partner With The Company
  • Profiles Of The 15 Companies, 2018

Charts & Tables for Each of the 15 Companies

  • Profile of respondent mental-health patient groups familiar, and working, with the company, 2018: country headquarters; geographic remit; and types of relationships.
  • Number of mental-health patient groups claiming familiarity with the company, 2018.
  • Number of mental-health patient groups saying that they had a working relationship with the company, 2018.
  • Company scores among mental-health patient groups familiar with the company, and which worked or partnered with the company, for each of the 12 indicators of corporate reputation, 2018.
  • Percentage of the mental-health patient groups that worked or partnered with the company, but which also worked with other companies, 2018.
  • Snapshot view: where the company sits in the tiers for each of the 12 indicators of corporate reputation (in the higher, the middle, or the lower tier), as assessed by mentalhealth patient groups familiar with the company, 2018.
  • The company's Patient Corporate Reputation Index (PCRI), 2015-2018.
  • Overall rankings for the company, according to mental-health patient groups familiar with the company, 2018 v. 2017.
  • Overall rankings for the company, according to mental-health patient groups that work or partner with the company, 2018 v. 2017.
  • Company rankings for each of the 12 indicators, according to mental-health patient groups familiar, or working, with the company, 2018 v. 2017.
  • The company's Net Promoter Score (NPS).

Companies Mentioned

  • Allergan
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly
  • GSK
  • Janssen
  • Lundbeck
  • Otsuka
  • Pfizer
  • Roche/Genentech
  • Sanofi
  • Takeda/Shire
  • Teva

For more information about this report visit https://www.researchandmarkets.com/r/ova3z7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900